Skip to main content
. 2014 Dec 9;35(1):52–62. doi: 10.1128/MCB.00525-14

FIG 5.

FIG 5

FHL2 deficiency attenuates LXR target gene expression. (A to C) SMCs derived from WT and FHL2-KO mice were treated with LXR agonists and assayed by qRT-PCR for mRNA expression of ABCA1 (A), IDOL (B), and LPL (C). (D) qRT-PCR was performed to assess mRNA expression of ABCA1 in SMCs from WT and FHL2-KO mice after incubation in SFM, LPDS, or LPDS and simvastatin followed by treatment with the natural ligands 25-hydroxycholesterol and desmosterol. (E) Western blot analysis of ABCA1 expression in WT and FHL2-KO SMCs. β-Actin was used as a loading control. (F) qRT-PCR was performed to assess mRNA expression of LXRs and LXR target genes in the aortas from WT and FHL2-KO mice. (G) Expression of ABCA1 and IDOL in human SMCs was determined by qRT-PCR after knockdown of FHL2 using lentiviral particles encoding shFHL2#1 and shFHL2#2. shCtrl is a scramble control. All experiments were performed in triplicate and repeated at least three times. Values are means and SD. #, P < 0.05 for nontreated versus agonist-treated cells; *, P ≤ 0.05 for shCtrl versus shFHL2; ns, not significant.